Company Leadership

Our story began with deep insights uncovered from truly listening to patients and healthcare providers.

The alignment, focus and dedication of our leadership team comes from a shared passion for improving the quality of health outcomes. We take pride in our engaged team who strive to bring a depth of experience, drive data-driven integrated solutions and support healthcare professionals in diagnosing patients threatened by cardiac arrhythmias, potentially preventing more serious medical events such as stroke.

Leadership Team

 
Jon P. Otterstatter
|
Chief Executive Officer

Jon Otterstatter is the original co-founder of Preventice Technologies in 2007; formerly known as Preventice. He currently serves as the Chief Executive Officer since 2016. Jon earned a reputation as a creative, solutions-oriented leader and technology visionary. His skills and commitment to excellence have brought high value to global enterprises while returning above-average value for stakeholders. Prior to co-founding Preventice, Jon served as Executive Vice President and Chief Technology Officer for SPSS. While at SPSS, he guided the strategic direction, budget, personnel and daily operations for the company’s worldwide technology operations. He also served as Senior Vice President of Technology for ShowCase Corporation in Rochester, MN, and was a Senior Programming Manager at IBM. Jon holds a Master ’s degree in Technology Management from Massachusetts Institute of Technology (M.I.T.), and a Bachelor’s degree in Computer Science from the University of Wisconsin-La Crosse.

 
Emily Benner
|
Executive Vice President Research and Product Development

Emily Benner serves as the Executive Vice President of Research and Development. She joined the company in 2013. In her role, Emily leads and directs the research of future product opportunities. Emily brings over 24 years of experience to the company. She held executive roles at IBM in firmware development, development of operating systems, and strategic technical development partnerships with large multi-national corporations such as SAP and Oracle. Prior to joining the company, Emily was a software director at IBM where she led large development teams of 300-500 people located in the U.S., Mexico, Germany, and India. Benner holds a Bachelor’s degree in electrical engineering from the University of North Dakota, a master ’s degree in computer engineering from the University of Minnesota, and a MBA from the University of Minnesota’s Carlson School of Management.

 
DAVID ISENHOUR
|
Executive Vice President of Operations and General Manager of the Houston site

David Isenhour serves as the Executive Vice President of Operations and General Manager of the Houston site. He joined the company in 2018. In his role, David focuses on delivering high-quality products, technologies and services to help Preventice exceed the expectations of patients, customers, and employees every day. This team is comprised of supply management, manufacturing, supply chain, and business services. David brings over 25 years of experience to the company. Prior to joining the company, David has held executive level positions within IBM where he focused on global business development, strategic technology alliances, product management, software and hardware development, M&A and corporate logistics. He repeatedly diagnosed and created opportunities to institute new models for operating at scale and unlocking value. David holds a Master’s degree in Technology Management from MIT and Bachelor of Science in Materials Engineering from North Carolina State University.

 
Ryan Ranweiler
|
Chief Financial Officer

Ryan Ranweiler serves as Chief Financial Officer, Secretary and Treasurer. He brings 20 years of senior financial leadership in mobile advertising, media and technology. In his role, Ryan is responsible for leading the finance, collections, human resources and legal teams. Prior to Preventice, Ryan served as Chief Financial Officer for Sportradar U.S., a SaaS platform delivering sports statistics worldwide. From 2005 to 2015, Mr. Ranweiler held various executive positions at NativeX, a leading mobile advertising technology provider, most recently Senior Vice President, CFO and Secretary. While at NativeX, Ryan was responsible for finance, human resources, legal and certain areas of operations and was responsible for helping deliver 9 consecutive years of positive EBITDA. Prior to joining NativeX, Ryan was a manager at Clifton Larson Allen where he provided attestation services and buy/sell-side diligence to companies in support of their M&A activities. He began his career at Grant Thornton (Minneapolis) and received a Bachelor's degree in accounting from the University of Northwestern – Saint Paul. He holds an active certified public accountant (CPA) and chartered global management accountant (CGMA) license.

Board of Directors

 
William Taranto
|
President Merck Global Health Innovation Fund LLC and Chairman, Preventice Solutions

Bill Taranto is President, Merck Global Health Innovation Fund LLC and Vice President, Global Health Innovation Group (GHI). Mr. Taranto is responsible for building the global health innovation (GHI) capability for Merck. The Merck Global Health Innovation (GHI) invests in emerging companies that deliver breakthrough healthcare solutions and which advance Merck's mission to discover, develop and provide innovative products and services that save and improve lives. GHI has a focused strategic investment approach designed to unlock the full value of health care innovations from around the world. As a strategic growth investor, GHI's goal is to grow emerging healthcare solutions into meaningful businesses. Established in 2010 as an independent LLC, GHI deploys its evergreen $500 million fund to rapidly identify and develop transformative global healthcare opportunities. GHI is focused on identifying opportunities that are adjacent to Merck’s core business of pharmaceuticals and vaccines. Mr. Taranto is a member of the Innovative Ventures Board, a group that manages the identification and funding of portfolio businesses; and is also head of the GHI Fund LLC Management Board. Mr. Taranto is also a board member of the Imperial College of London's Intellectual Property Research Centre. Prior to joining Merck, Mr. Taranto spent 18 years at Johnson & Johnson in various marketing, sales and business development roles with increasing responsibility. In his previous position, Executive Director, Health Care Strategy & Alliances, he was responsible for evaluating the future healthcare environment, the viability and impact of healthcare channels, and the creation of new healthcare business models. Mr. Taranto started his career as a sales representative for Janssen Pharmaceutica and progressed through various sales and marketing positions, including an assignment in Beerse, Belgium. Prior to joining Johnson & Johnson, Mr. Taranto spent eight years in investment banking. Mr. Taranto has a Bachelor of Business Administration from St. Bonaventure University.

 
Charlie Attlan
|
Senior Vice President, Corporate Strategy and Business Development, Boston Scientific

Charlie has been Senior Vice President, Corporate Strategy and Business Development at Boston Scientific Corporation (BSC) since 2010. His team is responsible for corporate strategic planning as well as coordinating the identification, assessment and execution of business development transactions including acquisitions, VC/minority investments, divestitures, licensing deals, and joint ventures. BSC has been amongst the most active investors in medical technology over the past 10 years, having completed over 35 acquisitions across size ranges from sub $10 million to several $ billions, as well as building a venture capital portfolio of over 40 investments across strategic areas of interest. Prior to BSC, Charlie spent 16 years in investment banking in New York, Chicago, and Paris (France) at Credit Suisse First Boston / Donaldson Lufkin & Jenrette (from 1999 til 2009) and Bankers Trust /BT Alex Brown (1993-1999).  Charlie grew up and went to high school in France, and received a Bachelor of Arts in Economics from Princeton University.

 
Larry Lawson
|
Board Member

Larry Lawson, a highly successful entrepreneur, founded eCardio Diagnostics in 2004, which is operating as Preventice Services. With more than 45 years of medical device industry and healthcare industry experience, Larry draws on his extensive market development and commercialization expertise to identify opportunities to advance arrhythmia diagnostic solutions. As an experienced healthcare executive and entrepreneur, Larry was founder and CEO of Diagnostic Monitoring Associates (DMA), a national marketing and sales firm specializing in the development and delivery of cardiac services to physician practices. Prior to DMA, he held various positions within healthcare companies, including executive management responsibilities at Johnson & Johnson, Edward Weck & Co., and Deseret Medical. He achieved success with several early-stage medical device companies including Life Med Technologies and Futuremed Interventional.

 
Jon P. Otterstatter
|
Chief Executive Officer

Jon Otterstatter is the original co-founder of Preventice Technologies in 2007; formerly known as Preventice. He currently serves as the Chief Executive Officer since 2016. Jon earned a reputation as a creative, solutions-oriented leader and technology visionary. His skills and commitment to excellence have brought high value to global enterprises while returning above-average value for stakeholders. Prior to co-founding Preventice, Jon served as Executive Vice President and Chief Technology Officer for SPSS. While at SPSS, he guided the strategic direction, budget, personnel and daily operations for the company’s worldwide technology operations. He also served as Senior Vice President of Technology for ShowCase Corporation in Rochester, MN, and was a Senior Programming Manager at IBM. Jon holds a Master ’s degree in Technology Management from Massachusetts Institute of Technology (M.I.T.), and a Bachelor’s degree in Computer Science from the University of Wisconsin-La Crosse.

 
Joseph Volpe
|
Vice President/ Managing Director, Merck Global Health Innovation Fund and General Manager, Merck Health Innovation PE Fund

Joe has more than two decades of experience in healthcare investing applying a technical engineering background coupled with an understanding of emerging technologies. He is considered to be one of the industry’s leading corporate investors. In 2016, Joe was named by Global Corporate Venturing as one of the top five rising stars. Joe currently holds board seats with Prognos (Medivo), Liaison/Remedy, Preventice, ClearDATA, Exostar and MiHealth. Previously he sat on the boards with Aptus (Physicians Interactive), Healthsense and Koneksa. Colleagues have called Joe instrumental in transforming Merck GHIF from a leader, not only in venture capital, but also in growth equity and M&A. He earned industry laurels when he participated in the sale of Humedica, a healthcare analytics company, to UnitedHealth Group in 2013, a transaction that produced a 17-fold return. In addition to his success with Humedica, Joe has led investments and acquisitions in companies such as Liaison, Preventice, Physicians Interactive, Koneksa, Prognos, WellDoc, Exostar, Milheath and ClearDATA. He has evaluated thousands of digital health companies and has invested in two to three companies annually since 2011. During that same period, he has also managed 40-plus transactions at Merck, all at various stages of maturity. Another notable success for Joe was his leadership with Preventice to further develop its remote care monitoring platform for cardiac arrhythmia patients. Joe led the Merck strategy and merger of Preventice with eCardio and eventually sold a portion of the combined company to a leading healthcare channel partner, which paid back the fund for the original investment while maintaining majority share of a more valued company. Joe also focused on the patient/physician engagement space with his Physicians Interactive (now called Aptus) investments. He eventually led the acquisition of the company on behalf of Merck GHIF. Joe also led the acquisitions of MedHelp, Quantia MD and Tomorrow Networks. Joe came to Merck from Johnson & Johnson where he spent more than 20 years in innovation and investment roles across Consumer, Pharma and Device sectors. Prior to that he was a consultant with EDS where he graduated from their Top Gun business and technology program. He went to the University of South Florida where he obtained a degree in Business/Information Systems and Engineering.